Furin (also known as PACE and SPC1) 1 is emerging as an important protein target for therapeutics in the search for antidotes for aggressive biological threats. Furin is a member of the subtilisin-like proprotein convertases (SPCs). These structurally related serine proteases are located within the secretory pathway of the cell, where they cleave protein precursors at the C-terminal side of single or paired basic residues (1-3). The inactive precursors processed by SPCs are transformed to biologically active hormones, receptors, growth factors, neuropeptides, and enzymes. SPCs, and especially furin, also play a major role in pathogenesis (4, 5) . Human furin processes elements of various bacterial toxins, including anthrax, diphtheria, shigella, and pseudomonas, enabling their entry into host cells. This is achieved by furin molecules on the outer surface of the host cell plasma membrane or in the endocytic pathway (4, 5) . In the trans Golgi network, furin processes the envelope glycoproteins profusogens of many viruses during their biosynthesis. In the absence of processing by furin, new viruses released from the host cell are unable to fuse with uninfected cells. Viruses exploiting human furin include ebola, HIV-1, measles, avian influenza, Newcastle disease virus, and cytomegalovirus (4 -6) . Because furin is expressed in practically all body tissues and cell types (5) , and because it is essential for the effects of so many aggressive pathogens, its inhibitors may be envisioned as wide spectrum antidotes against known and even unknown biological threats (7) . Such broad spectrum intervention may be most useful in an unexpected bioterror attack.
Inhibition of purified furin and the other SPCs has been demonstrated with proteins and peptides (3, 5, 6) . These include: (a) natural endogenous inhibitors of SPCs, (b) prodomains that are part of the inactive pro-SPC (these block pro-SPC proteolytic activity during synthesis and are removed by post-translational modification), and (c) peptides that have no physiological connection to the activity of SPCs. A few of these inhibitors are potent, reaching IC 50 values in the low nanomolar range (3, 6, 8) .
The only non-protein, non-peptide inhibitor of furin reported to date is a neoandrographolide, a diterpene lactone extracted from the medicinally active plant Andrographis paniculata, and its succinoyl ester derivatives (9) . The IC 50 values reported are in the high micromolar and low millimolar range. Here we report the inhibition of furin by copper and zinc complexes of terpyridine derivatives, with IC 50 values of 5-10 M (k on ϭ 120 -140 s Ϫ1 ). Our compounds are stable under various conditions and are not expected to pose delivery problems, qualities vital for the development of a wide-scope anti-bioterror agent for civil and military uses.
EXPERIMENTAL PROCEDURES
Enzyme, Substrate, and Reagents-Substrate BOC-Arg-Val-ArgArg2MCA (BOC, t-butoxycarbonyl; MCA, methylcoumarinamide) was purchased from Bachem. Its concentration was determined according to the released 7-amino-4-methylcoumarin (AMC) product fluorescence after complete digestion with Kex2. To minimize degradation, the substrate was aliquoted and kept frozen (Ϫ20°C) in dimethyl sulfoxide (Me 2 SO) until use. Furin (10 -12) and Kex2 (13) were prepared as described previously. The C217S mutant of Kex2 2 was prepared according to the same procedure. Salts for buffers and other standard reagents were from Sigma or Fisher, ACS grade or higher. Solvents for organic syntheses were from Fisher or Acros, ACS grade or higher. Chelates and ligands were purchased from Aldrich (except for 4Ј-[4-methoxyphenyl]-2,2Ј:6Ј,2Љ-terpyridine (MPT), which was from Alfa-Aesar) at the highest purity level available and were used without further processing. Zn(chelate)Cl 2 compounds were prepared according to published procedures (14, 15) that were slightly modified, according to the preparation of Cu(TERPY)Cl 2 (TERPY, 2,2Ј:6Ј,2Љ-terpyridine) (16) . Other Cu(chelate)Cl 2 compounds were prepared according to the same modified procedure (16 
(17) in the model shown in Reaction 1,
in the model shown in Reaction 2. 18) , and the product formation rate was monitored as described for furin. Because zinc compounds formed with aryl derivatives of TERPY during the inhibition (or prepared before it) were fluorescent (15), the activities obtained at high inhibitor concentrations (Ͼ250 M) were too low (deviating from the exponential fit). In these cases, IC 50 values (all lower than 250 M) were obtained using only low inhibitor concentration data. This was a problem only with Kex2, as it was less sensitive to our inhibitors than furin.
Determination of Irreversibility-Furin (15 nM) was incubated at 22°C for 2 h in assay buffer and either Zn(TTP)Cl 2 (at 9, 18, or 34 M), Cu(TTP)Cl 2 (at 0.6, 2.4, or 9.6 M), ZnCl 2 (at 12.5, 50, or 250 M), CuCl 2 (at 0.6, 2.4, or 7.2 M), or no inhibitor at all. With Cu 2ϩ , the experiment was repeated using 8 min of incubation, giving results that were identical to the longer incubation period. Each inhibitor concentration was run in two independent tubes. Reactions were then diluted 100-fold with buffer. Substrate (100 M) was added, and AMC product release was monitored for 2 h as described above for the inhibition assays.
(Longer monitoring was not useful because of loss of furin activity at 30°C.) Rates of AMC product release after dilution were obtained from a linear fit to data points between 2,000 and 7,200 s. Activities prior to dilution were determined on an aliquot set aside from the same reaction mixture, using the procedure described above for the inhibition assays. The same procedure was employed with Kex2, with a few differences. Kex2 (6 nM) and either a 1:1 mixture of TTP and ZnCl 2 (250 or 1,200 M), ZnCl 2 only (2.5 or 5 mM), or no inhibitor at all were incubated at 22°C for either 30 or 90 min in assay buffer. Incubation periods were short to avoid complete inhibition. Dilution and assay procedures were the same as with furin. Rates of AMC product release after dilution were obtained from a linear fit to data points between 1,000 and 4,000 s.
Determination of Kinetic Constants-Furin (at 1.5 nM to avoid substrate depletion) was added to mixtures in 96-well plates that included a constant amount of inhibitor (30 M Zn(TTP)Cl 2 , 200 M ZnCl 2 , 12 M Cu(TTP)Cl 2 , or 100 M CuCl 2 ) and a varied amount of substrate (between 4.5 (K m /4) and 36 M (2K m )) in assay buffer. Each substrate concentration was checked in at least two independent wells. After mixing, the release of AMC product was monitored at 30°C for at least 2 h as described above for the inhibition assays. The fluorescence emitted by Zn(MPT)Cl 2 at 460 nm (the wavelength used to monitor product concentration) prevented us from reliably monitoring the action of this complex. This was not a problem with Zn(TTP)Cl 2 . Individual traces were fit according to Equation 4 ,
where P is [product], a is vertical correction, k obs is the apparent inactivation rate constant, v o is the rate of uninhibited reaction, v s is the product formation rate at equilibrium with inhibitor, v hv is the rate of photochemical product degradation, t is time (17, 19) with v s ϭ 0 whenever the inhibition was irreversible. Equation 4 simulates slow binding inhibitors. We added the v h ⅐t term to account for slow photochemical degradation of the AMC product (20) , which is first order in substrate and zero order in metal and chelate (19) . We did not examine the kinetics of a 1:1 mixture of M ions (M is Zn 2ϩ , Cu 2ϩ ) and chelate here, because [M(chelate)] 2ϩ formation is heavily favored. Thus, the changes in active inhibitor concentration could not be treated under the steady state approximation. This was not a concern with the preincubated experiments, where active inhibitor formation was completed well before substrate addition.
The kinetic follow-up with Kex2 was similar to that with furin. 0.03 nM Kex2 was added to mixtures that included 19 M substrate and either Zn(TTP)Cl 2 (at 0 -140 M, concentration limited by compound fluorescence) or ZnCl 2 (at 0 -3.5 mM) in assay buffer. Monitoring the product release rate was as described for furin.
RESULTS
Enzyme inhibition experiments included incubation of chelate and metal salt (or of the preassembled metal-chelate complex) together with the enzyme at 22°C, followed by addition of the substrate BOC-Arg-Val-Arg-Arg2MCA. Inactivation was quantified from the initial rate of fluorescent AMC product release. The results with zinc and its complexes are presented in Table I (see also Scheme 1) and those with copper in Table II .
Inhibition by Zinc and Its Compounds-The trends among the various chelates were similar for furin and Kex2, but furin was more susceptible to the inhibition by about two orders of magnitude (Table I and see also k on values below). Zinc complexes of the aromatic derivatives of TERPY were the only inhibitors more efficient than solvated Zn 2ϩ . Yet, all zinc-chelate combinations afforded some degree of inhibition except for Zn(t-Bu 3 -TERPY)Cl 2 which is probably too bulky. The free chelates by themselves had no affect on enzyme activity. In similarity to copper and Kex2 (19) , inhibition enhancement was maximized at a 1:1 ratio of metal to tridentate, suggesting that the active inhibitor has only one tridentate bound to zinc. In support of this conclusion is the observation that inhibition by preassembled complexes was practically the same as, or slightly better than inhibition by the corresponding mixtures of solvated Zn 2ϩ and chelate (which formed the complexes in situ). These findings justify the use of preassembled complexes to study the inhibitory effects. We did so whenever a free tridentate chelate was insufficiently soluble, or when kinetic constants were obtained.
Inhibition Is Irreversible-Dilution experiments reveal that furin and Kex2 inhibition by Zn(TTP)Cl 2 was irreversible. To examine reversibility, the enzymes were preincubated with the inhibitor, reactions were diluted 100-fold by buffer, and substrate was added. Reaction monitoring was initiated immediately afterward (Fig. 4 shows a similar looking experiment with solvated Cu 2ϩ ). When product formation was resumed after the dilution, product accumulation rates were linear with time. However, the slopes were not parallel; the higher the initial inhibitor concentration, the slower the product formation rate. This indicates that even after dilution, furin retained a substantial fraction of the inhibitor bound. The linearity of the kinetic traces indicates that inhibitor dissociation (resulting in higher active enzyme concentration and increasing reactivity) did not take place after enzyme activity was resumed. The residual enzyme activity after dilution (calculated from the slopes of the kinetic traces) and before dilution (calculated from dose-response correlation using a set-aside portion of the nondiluted solutions) shows that there was no increase in active enzyme concentration after the dilution (product formation rates differ according to the dilution factor). This holds true for both furin and Kex2 at all the concentrations examined.
Furin and Kex2 inhibition by Cu(TTP)Cl 2 was similar to that by Zn(TTP)Cl 2 , and likewise irreversible. But this was not the case with the solvated metal ions. With furin, the residual activity after dilution was higher than before dilution by a factor of 7 for Zn 2ϩ (at 250 M, the highest inhibitor concentration examined, 65% of the initial uninhibited activity was observed instead of 8%). With Cu 2ϩ , the activity after dilution was higher by a factor of 3 (22% at 7.2 M Cu 2ϩ instead of 7%). This indicates that some of the bound metal ions (but not the complexes) dissociate from the protein during the dilution process. Metal dissociation is complete within the time needed for the protein to resume product formation. This suggests two modes of inhibition by Zn 2ϩ : one irreversible (linear kinetic traces), the other reversible (rapid but partial metal dissociation upon dilution). Partially reversible inhibition by the solvated metal ions was also observed with Kex2. With 2.5 mM Zn 2ϩ the activity was 46% prior to the dilution, but 53% after. (Table II) .
Unlike our findings with Kex2 and copper (19) , the effect of chloride on Kex2 inhibition by Zn 2ϩ and its compounds and on furin was negligible.
Mutational Analysis-Cys 217 of Kex2 is adjacent to the catalytic His 213 . It is not known whether it takes part in catalysis (21), although it is a potential site for metal binding within the active site. A C217S mutant of Kex2 was constructed, expressed, and purified (data not shown). The mutant enzyme was enzymatically active, although activity was reduced (roughly 5-fold; characterization of the effects of this mutation on catalysis will be published elsewhere). Using normalized inhibition tests (Table III) we found that the mutation had some effect on the inhibition by solvated Zn 2ϩ and Cu 2ϩ , but none on the inhibition by the complexes [Cu(TERPY)Cl] ϩ and Zn(TTP)Cl 2 .
Inhibition by Copper and Its Compounds-Furin inhibition with solvated copper ions and copper complexes was similar to that with zinc and to our previous observations with Kex2 (19) in being competitive with substrate (Figs. 1, 2, 3 , and 5), in being irreversible with complexes, and in having two metal ion populations: one reversibly bound and one irreversibly bound (dilution experiments, Fig. 4 ). As we have seen with zinc, all copper-chelate compounds exhibited some degree of furin inhibition (Table II) , except for [Cu(TERPY) 2 ] 2ϩ , which has no coordination sites available for target binding. Copper compounds of TERPY chelates substituted at the 4Ј position by an aryl group were consistently the best, but this time the advantage in modifying TERPY was very small (Table II) .
Unlike our previous examples, all metal-tridentate complexes tested with furin were much inferior in potency to the solvated Cu 2ϩ ions. As a result, the mixture of solvated Cu 2ϩ Table I for furin. The loss of product fluorescence that is observed at higher inhibitor concentrations is caused by product photochemical degradation (19, 20) . This loss is first order in AMC, but zero order in inhibitor. and free chelate was superior as a furin inhibitor to the preprepared complex (by at least one order of magnitude) because of the remaining uncomplexed copper ions in the mixture. This became obvious when preincubation of copper and tridentate chelate in the absence of enzyme led to reduced inhibition under any of the following conditions: longer preincubation times, higher TERPY/copper ratios, and higher TERPY ϩ Cu 2ϩ concentrations (at constant TERPY/copper ratios).
FIG. 2. Kex2 inhibition progress curves at different [S]
Furin inhibition by solvated Cu 2ϩ was unique also in revealing two phases during kinetic follow-ups (Fig. 5 ). The first phase was similar to all other inhibitions we observed, although it was completed much faster (within ϳ1,000 s). However, furin resumed product formation after a lag time. This recovery was more pronounced at higher substrate concentrations. A second, slower inhibition phase was observed within the duration of our experiment (Fig. 5) . At substrate concentrations higher than those shown, only one inhibition phase is apparent. Observation of the recovery of furin activity after inhibition is limited to a narrow window of solvated Cu 2ϩ concentrations. At 2.5 M Cu 2ϩ (and 9 M substrate) there is no recovery of activity after inhibition, whereas at 20 nM (1.33:1 inhibitor to furin ratio) we see very little inhibition (Fig. 6) . It should be noted that our dose response results with solvated Cu 2ϩ (Table II) were completed within 10 min after substrate addition, well before furin activity recovery was noticeable.
Treating the kinetic follow-up data for the first phase only (t Ͻ 1,000 s) by the same model we used for zinc and its compounds (Reaction 1) yielded a k on of 25,000 Ϯ 2,500 s Ϫ1 (Fig. 7) . Using the same model for Cu(TTP)Cl 2 we got k on ϭ 140 Ϯ 13 s Ϫ1 (Fig. 8) . As we found earlier with zinc, the simplified model in Reaction 2 yielded values with no physical FIG. 4 . Product formation by furin after 100-fold dilution of incubations with solvated Cu 2؉ at 0.6, 2.4, and 7.2 M, or with no inhibitor at all (control). Enzyme (15 nM) and inhibitor were incubated for 2 h at 22°C. Reactions were diluted 100-fold by buffer, substrate (100 M) was added, and product formation was monitored. Product formation rates after dilution were obtained from a linear fit to data points between 2,000 and 7,200 s. Activities prior to dilution were determined with aliquots set aside from the same solutions, according to the procedure outlined under Table I meaning, and the model was rejected. Applying the two models shown in Reactions 1 and 2 for the second phase of the inhibition by Cu 2ϩ (t Ͼ 3,000 s) did not yield reasonable results (k on was too large or K i negative, respectively). This and the shape of the kinetic traces (Fig. 5) suggest the latter phase to be reversible. Because of the slow photochemical decomposition of the product (Refs. 19 and 20 and Figs. 1-3 ) and because v s 0, we do not have sufficient data to extract the kinetic parameters using a fully reversible kinetic model.
Inhibition by Solvated Mercury Ions Hg 2ϩ -We wanted another demonstration of the peculiar sequence of events in furin inhibition caused by solvated Cu 2ϩ (Figs. 5 and 6 ). Because mercury ions inhibit proteinase K (a homologue of Kex2 and furin), (22) and because mercury has higher cysteine affinity than either copper or zinc, it seemed logical to test furin inhibition by solvated Hg 2ϩ . Inhibition (IC 50 ϭ 200 nM) was somewhat less efficient than with solvated Cu 2ϩ , but better than with solvated Zn
2ϩ . Yet, we were unable to find conditions under which an inhibition-recovery-inhibition sequence (similar to Figs. 5 and 6) could be observed with mercury. (Table I) . For both proteins, the inhibition: (a) was irreversible, (b) was competitive with substrate, (c) exhibited kinetics following the simplified model in Reaction 1, (d) was as efficient or slightly more efficient with preassembled metal-chelate complexes than when complexes were formed in situ from a mixture of Zn 2ϩ and the tridentate chelate, and (e) exhibited the same trends with the various inhibitors. These similarities imply that both enzymes are inhibited by similar mechanisms. The major difference between furin and Kex2 inhibition was in the two orders of magnitude higher potency of all zinc-based inhibitors toward furin. According to the suggested mechanism, this is due (at least in part) to the higher solvent accessibility of the catalytic His 194 in furin. In Kex2, Tyr 212 is situated between catalytic His 213 and the solvent. However, there is no residue with similar positioning in furin (21, 23) .
Inhibitor Binding Involves Metal Coordination-None of the free chelates tested inhibited Kex2 (at 800 M or below) and furin (at 400 M). Yet, all combinations involving zinc afforded some inactivation (Table I) , indicating metal coordination to protein in all cases. Comparison with our copper data (Table II and Ref. 19 ) suggests a lower protease affinity for zinc. Binding was sufficiently strong to overcome all ligand interferences (except with the bulky t-Bu 3 -TERPY). The strength of the zinc protein binding is manifested also in the irreversibility of the inhibition.
Inhibitors . C217S Kex2 was somewhat less susceptible than the wild-type (WT) enzyme to inhibition by solvated copper, whereas inhibition by solvated zinc was facilitated (Table III) . This implies a difference between the Kex2 binding modes of the complexes and the solvated ions during inhibition.
Binding of Zn(tridentate)Cl 2 -An obvious difference between the complexes and the solvated metal ions is in the availability of more sites to coordinate to the enzyme on the ions. The tridentate chelate occupies three coordination sites in each complex. Because zinc is usually present in a tetrahedral environment when coordinated to proteins (25) , the complexes are most likely to form only a single coordination bond to Kex2. Moreover, Zn-N bonds are stronger in tetrahedral compared with octahedral environments (26, 27) . A well known example is that when bound only to histidines in zinc fingers, zinc ions bind to four such residues. This effect is more prominent in the presence of multiple metal-nitrogen bonds. Our complexes have three Zn-N bonds, and a fourth forms upon binding to a Kex2 (1)) or the intercept (k on (2) (Table II and Fig. 3 ) were similar in every regard to those obtained with the zinc complexes. Hence, a similar mechanism is indicated.
Inhibition by Solvated Zn 2ϩ -Furin inhibition by solvated Zn 2ϩ ions showed close similarity to the inhibition of Kex2, just as we found with the zinc-chelate complexes (Table I) . For both enzymes the inhibition was: (a) irreversible with most of the solvated Zn 2ϩ population, but reversible with the rest; (b) competitive with substrate; and (c) with kinetics that followed the simplified model in Reaction 1. These similar observations suggest that furin and Kex2 are inhibited by solvated Zn 2ϩ by a similar mechanism. However, because the mutational analysis was done only with Kex2, we could elucidate the mechanism of inhibition by solvated Zn 2ϩ for this enzyme first. Unlike [Zn(chelate)] 2ϩ , solvated Zn 2ϩ can replace more than a single water ligand by stronger metal-protein coordination bonds. Proteinase K (a homologue of Kex2 and furin) forms two strong bonds (and some weaker ones) to Hg 2ϩ by stepwise binding to the catalytic histidine and to a subsequently exposed, nearby conserved cysteine (22, 28 (21) .
A combination of the first two inhibition options is necessary to explain our observations for Kex2 inhibition by Zn 2ϩ . There is no reason to invoke a role for binding option c. However, the somewhat higher (20%) IC 50 for the inhibition of C217S Kex2 (23) and Kex2 (21) using RasMol Macintosh version 2.7.2.1. The distances should be treated as guidelines only, because the imidazole rings can rotate around the histidine C(␤)-C(␥) axis. This is well demonstrated in the structure of furin, which in this case is an octamer. The distance between the same atoms in different units differs by more than 0.1 Å (for this reason only a single digit beyond the decimal point is given). In solution, upon imidazole rotation around the histidine C(␤)-C(␥) axis in combination with ligand binding, the distances will change by much more. It should be noted that the table refers to 5 atoms (2 nitrogens from each histidine imidazole and 1 cysteine sulfur), but for binding the metal ions we need only a single nitrogen from each histidine, and the sulfur. Hence, the longer distances from N␦ (1) 
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